Journals / European Archives of Medical Research / 2022 / Cilt: 38 - Sayı: 1

The Metastatic Lymph Node Ratio is a Crucial Criterion in Colorectal Cancer Therapy Management and Prognosis

Pages
73–79
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Factors such as age, gender, tumor location, tumor size, T stage, lymphovascular invasion, perineural invasion, tumor budding, tumor deposit, total and mLN count were evaluated for overall survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Every year, 1.8 million people are diagnosed with colon cancer.
📊
Key Findings & Data:Methods: Pathology reports of 496 stage II and stage III patients treated for colorectal cancer (CRC) in our hospital in the last decade were retrospectively reviewed.
💡
Conclusion & Impact:Factors such as age, gender, tumor location, tumor size, T stage, lymphovascular invasion, perineural invasion, tumor budding, tumor deposit, total and mLN count were evaluated for overall survival.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Every year, 1.8 million people are diagnosed with colon cancer. The presence of lymph node (LN) metastases is a key prognostic factor in adjuvant treatment planning and follow-up. The tumor-node-metastasis (TNM) classification can be used to assist in prognostic cancer staging. However, TNM-classification may not always compromise the necessary prognostic information. Therefore, guidelines are updated regarding prognostic value and new prognostic parameters are investigated. One of these parameters is metastatic lymph node ratio (mLNR), which is calculated by dividing the number of metastatic lymph nodes (mLNs) by the total number of lymph nodes excised. Similar publications have already reported on the prognostic value of the mLNR in gastric, pancreatic, and bladder cancer. Methods: Pathology reports of 496 stage II and stage III patients treated for colorectal cancer (CRC) in our hospital in the last decade were retrospectively reviewed. Factors such as age, gender, tumor location, tumor size, T stage, lymphovascular invasion, perineural invasion, tumor budding, tumor deposit, total and mLN count were evaluated for overall survival. Results: The mean tumor size was 53.8 mm. The patients who had an average of 2 LN involvement among those who had 23 lymph nodes excised were followed up for an average of 66.8 months. Receiver operating characteristic test presented the cut-off value of mLNR on overall survival was 0.028, with a sensitivity of 42% and a specificity of 71%. Gender, tumor’s localization, and size of ≥6 cm had no significant impact on survival. However, survival was related to age >60, lymphovascular, and perineural invasion, tumor deposit/budding, and mLNR >0.028 (p≤0.05). Furthermore, multivariate analysis revealed that only mLNR (p=0.034) affected overall survival independently. Conclusion: We believe that mLNR that does not require additional costs will gain more value in diagnosis and treatment. Based on our results, mLNR may be a useful to assess prognosis in CRC patients.

🔖

Cite This Article

KAMALI, G. H., KAMALI, S. (2022). The Metastatic Lymph Node Ratio is a Crucial Criterion in Colorectal Cancer Therapy Management and Prognosis. European Archives of Medical Research, Cilt: 38 - Sayı: 1, 73–79. https://ajindex.com/articles/510293

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394- 424
  2. Pei JP, Zhang CD, Fu X, Ba Y, Yue S, Zhao ZM, et al. A Novel TNM classification for colorectal cancers based on the metro-ticket Paradigm. J Cancer 2021;12:3299-306
  3. Weiser MR. AJCC 8th Edition: Colorectal cancer. Ann Surg Oncol 2018;25:1454-5
  4. Horne J, Bateman AC, Carr NJ, Ryder I. Lymph node revealing solutions in colorectal: should they be used routinely? J Clin Pathol 2014;67:383- 8
  5. Walker R, Wood T, LeSouder E, Cleghorn M, Maganti M, MacNeill A, et al. Comparison of two novel staging systems with the TNM system in predicting stage III colon cancer survival. J Surg Oncol 2018;117:1049- 57
  6. Pyo JS, Kim JH, Lee SY, Baek TH, Kang DW. Metastatic lymph node ratio (mLNR) is a useful parameter in the prognosis of colorectal cancer; a meta-analysis for the prognostic role of mLNR. Medicina 2019;55:673
  7. Kim MJ, Jeong SY, Choi SJ, Ryoo SB, Park JW, Park KJ, et al. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer. Ann Surg Oncol 2015;22:505-12
  8. Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, et al. The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. Anticancer Res 2014;34:2389-94
  9. Hou Y, Wang X, Chen J. Prognostic significance of metastatic lymph node ratio: the lymph node ratio could be a prognostic indicator for patients with gastric cancer. World J Surg Oncol 2018;16:198
  10. Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol 2017;30:1299-311
  11. Lord AC, D’Souza N, Pucher PH, Moran BJ, Abulafi AM, Wotherspoon A, et al. Significance of extranodal tumour deposits in colorectal cancer: a systematic review and meta-analysis. Eur J Cancer 2017;82:92-102
  12. Samawi HH, Yin Y, Speers CH, Cheung WY. Sex disparities in outcomes of early stage colorectal cancer: a population-based study. Clinical Colorectal Cancer 2018;17:e711-7
  13. Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol 2011;34:43-9
  14. Kamphues C, Andreatos N, Kru